


10/522,958
PU4870USw

In the Claims:

Please cancel claims 22, 24, and 31-32. Please amend claims 1, 20, 21, and 43 as follows.

1. (Currently Amended) A compound of formula (I):



wherein:

R¹ is selected from the group consisting of H, alkyl, alkenyl, alkynyl, -C(O)R⁷, -CO₂R⁷, -C(O)NR⁷R⁸, -C(O)N(R⁷)OR⁸, -C(O)N(R⁷)-R²-OR⁸, -C(O)N(R⁷)-Ph, -C(O)N(R⁷)-R²-Ph, -C(O)N(R⁷)C(O)R⁸, -C(O)N(R⁷)CO₂R⁸, -C(O)N(R⁷)C(O)NR⁷R⁸, -C(O)N(R⁷)S(O)₂R⁸, -R²-OR⁷, -R²-O-C(O)R⁷, -C(S)R⁷, -C(S)NR⁷R⁸, -C(S)N(R⁷)-Ph, -C(S)N(R⁷)-R²-Ph, -R²-SR⁷, -C(=NR⁷)NR⁷R⁸, -C(=NR⁷)N(R⁸)-Ph, -C(=NR⁷)N(R⁸)-R²-Ph, -R²-NR⁷R⁸, -CN, -OR⁷, -S(O)₂R⁷, -S(O)₂NR⁷R⁸, -S(O)₂N(R⁷)-Ph, -S(O)₂N(R⁷)-R²-Ph, -NR⁷R⁸, -N(R⁷)-Ph, -N(R⁷)-R²-Ph, -N(R⁷)-SO₂R⁸ and tetrazole Het;

Ph is phenyl optionally substituted from 1 to 3 times with a substituent selected from the group consisting of halo, alkyl, -OH, -R²-OH, -O-alkyl, -R²-O-alkyl, -NH₂, -N(H)alkyl, -N(alkyl)₂, -CN and -N₃;

Het is a 5-7 membered heterocycle having 1, 2, 3 or 4 heteroatoms selected from N, O and S, or a 5-6 membered heteroaryl having 1, 2, 3 or 4 heteroatoms selected from N, O and S, each optionally substituted from 1 to 2 times with a substituent selected from the group consisting of halo, alkyl, oxo, -OH, -R²-OH, -O-alkyl, -R²-O-alkyl, -NH₂, -N(H)alkyl, -N(alkyl)₂, -CN and -N₃;

Q¹ is a group of formula: $-(R^2)_a-(Y^1)_b-(R^2)_c-R^3$

a, b and c are the same or different and are each independently 0 or 1 and at least one of a or b is 1;

n is 0, 1, 2, 3 or 4;

Q² is a group of formula: $-(R^2)_{aa}-(Y^2)_{bb}-(R^2)_{cc}-R^4$

~~or two adjacent Q² groups are selected from the group consisting of alkyl, alkenyl, OR², S(O)₂R² and -NR²R⁸ and together with the carbon atoms to which they are bound, they form a C₃₋₆cycloalkyl, C₆₋₆cycloalkenyl, phenyl, 5-7~~

10/522,958
PU4870USw


~~membered heterocycle having 1 or 2 heteroatoms selected from N, O and S,~~
~~or 5-6 membered heteroaryl having 1 or 2 heteroatoms selected from N, O~~
~~and S;~~

aa, bb and cc are the same or different and are each independently 0 or 1;

each Y¹ and Y² is the same or different and is independently selected from the group
consisting of -O-, -S(O)₂-, -N(R⁷)-, -C(O)-, -OC(O)-, -CO₂-, -C(O)N(R⁷)-,
-C(O)N(R⁷)S(O)₂-, -OC(O)N(R⁷)-, -OS(O)₂-, -S(O)₂N(R⁷)-, -S(O)₂N(R⁷)C(O)-,
-N(R⁷)S(O)₂-, -N(R⁷)C(O)-, -N(R⁷)CO₂- and -N(R⁷)C(O)N(R⁷)-

each R² is the same or different and is independently selected from the group
consisting of alkylene, alkenylene and alkynylene;

each R³ and R⁴ is the same or different and is each independently selected from the
group consisting of H, halo, alkyl, alkenyl, alkynyl, -C(O)R⁷, -C(O)NR⁷R⁸,
-CO₂R⁷, -C(S)R⁷, -C(S)NR⁷R⁸, -C(=NR⁷)R⁸, -C(=NR⁷)NR⁷R⁸, -CR⁷=N-OR⁷,
-OR⁷, -S(O)₂R⁷, -S(O)₂NR⁷R⁸, -NR⁷R⁸, -N(R⁷)C(O)R⁸, -N(R⁷)S(O)₂R⁸, -NO₂,
-CN, -N₃ and a group of formula (ii):



wherein:

Ring A is selected from the group consisting of C₅₋₁₀cycloalkyl,
C₅₋₁₀cycloalkenyl, aryl, 5-10 membered heterocycle having 1, 2 or 3
heteroatoms selected from N, O and S and 5-10 membered heteroaryl
having 1, 2 or 3 heteroatoms selected from N, O and S

each d is 0 or 1;

e is 0, 1, 2, 3 or 4;

each R⁶ is the same or different and is independently selected from the group
consisting of H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl,
Ph, Het, -CH(OH)-R²-OH, -C(O)R⁷, -CO₂R⁷, -CO₂-R²-Ph, -CO₂-R²-Het,
-C(O)NR⁷R⁸, -C(O)N(R⁷)C(O)R⁷, -C(O)N(R⁷)CO₂R⁷,
-C(O)N(R⁷)C(O)NR⁷R⁸, -C(O)N(R⁷)S(O)₂R⁷, -C(S)R⁷, -C(S)NR⁷R⁸,
-C(=NR⁷)R⁸, -C(=NR⁷)NR⁷R⁸, -CR⁷=N-OR⁸, =O, -OR⁷, -OC(O)R⁷,
-OC(O)Ph, -OC(O)Het, -OC(O)NR⁷R⁸, -O-R²-S(O)₂R⁷, -S(O)₂R⁷,
-S(O)₂NR⁷R⁸, -S(O)₂Ph, -S(O)₂Het, -NR⁷R⁸, -N(R⁷)C(O)R⁸,
-N(R⁷)CO₂R⁸, -N(R⁷)-R²-CO₂R⁸, -N(R⁷)C(O)NR⁷R⁸,
-N(R⁷)-R²-C(O)NR⁷R⁸, -N(R⁷)C(O)Ph, -N(R⁷)C(O)Het, -N(R⁷)Ph,

10/522,958
PU4870USw

$-N(R^7)Het$, $-N(R^7)C(O)NR^7-R^2-NR^7R^8$, $-N(R^7)C(O)N(R^7)Ph$,
 $-N(R^7)C(O)N(R^7)Het$, $-N(R^7)C(O)N(R^7)-R^2-Het$, $-N(R^7)S(O)_2R^8$,
 $-N(R^7)-R^2-S(O)_2R^8$, $-NO_2$, $-CN$ and $-N_3$;

wherein when Q^1 is defined where b is 1 and c is 0, R^3 is not halo, $-C(O)R^7$,

$-C(O)NR^7R^8$, $-CO_2R^7$, $-C(S)R^7$, $-C(S)NR^7R^8$, $-C(=NR^7)R^8$, $-C(=NR^7)NR^7R^8$,
 $-CR^7=N-OR^7$, $-OR^7$, $-S(O)_2R^7$, $-S(O)_2NR^7R^8$, $-NR^7R^8$, $-N(R^7)C(O)R^8$,
 $-N(R^7)S(O)_2R^8$, $-NO_2$, $-CN$ or $-N_3$;

wherein when Q^2 is defined where bb is 1 and cc is 0, R^4 is not halo, $-C(O)R^7$,

$-C(O)NR^7R^8$, $-CO_2R^7$, $-C(S)R^7$, $-C(S)NR^7R^8$, $-C(=NR^7)R^8$, $-C(=NR^7)NR^7R^8$,
 $-CR^7=N-OR^7$, $-OR^7$, $-S(O)_2R^7$, $-S(O)_2NR^7R^8$, $-NR^7R^8$, $-N(R^7)C(O)R^8$,
 $-N(R^7)S(O)_2R^8$, $-NO_2$, $-CN$ or $-N_3$;

R^5 is selected from the group consisting of H, halo, alkyl, cycloalkyl, OR^7 , $-S(O)_2R^7$,

$-NR^7R^8$, $-NHC(O)R^7$, $-NHC(O)NR^7R^8$ and $-NHS(O)_2R^7$;

f is 0, 1 or 2; and

each R^7 and each R^8 are the same or different and are each independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl;

wherein when R^1 is $-CO_2CH_3$ and n is 0, Q^1 is not $-OH$;

or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.

2. (Original) The compound according to claim 1, wherein R^1 is selected from the group consisting of $-C(O)R^7$, $-CO_2R^7$ and $-C(O)NR^7R^8$.

3. (Original) The compound according to claim 1, wherein R^1 is selected from the group consisting of $-CO_2R^7$ and $-C(O)NR^7R^8$.

4. (Previously Presented) The compound according to claim 1, wherein b is 1.


5. (Previously Presented) The compound according to claim 1, wherein Q^1 is defined wherein b is 1 and Y^1 is selected from $-O-$, $-N(R^7)-$, $-C(O)-$, $-OC(O)-$, $-C(O)N(R^7)-$, $-OS(O)_2-$, $-S(O)_2N(R^7)-$, $-N(R^7)SO_2-$ and $-N(R^7)C(O)-$.

10/522,958
PU4870USw

6. (Original) The compound according to claim 5, wherein Q^1 is defined wherein b is 1 and Y^1 is selected from $-O-$, $-N(R^7)-$, $-C(O)-$, $-OS(O)_2-$, $-N(R^7)SO_2-$ and $-N(R^7)C(O)-$.


7. (Previously Presented) The compound according to claim 1, wherein c is 1.

8. (Previously Presented) The compound according to claim 1, wherein R^3 is selected from the group consisting of H, alkyl, alkenyl, alkynyl, and a group of formula (ii):




9. (Previously Presented) The compound according to claim 1, wherein R^3 is a group of formula (ii) and Ring A is selected from aryl, 5-10 membered heterocycle having 1, 2 or 3 heteroatoms selected from N, O and S and 5-10 membered heteroaryl having 1, 2 or 3 heteroatoms selected from N, O and S.

10. (Previously Presented) The compound according to claim 1, wherein R^3 is a group of formula (ii) and Ring A is selected from the group consisting of cycloalkyl, tetrahydropyran, tetrahydrofuran, morpholine, piperidine, phenyl, naphthyl, thiophene, furan, pyrrole, pyrrolidine, pyrrolidinone, imidazole, benzofuran, benzimidazole, pyridyl,



10/522,958
PU4870USw

11. (Previously Presented) The compound according to claim 1, wherein Q¹ is selected from the group consisting of



12. (Previously Presented) The compound according to claim 1, wherein R³ is a group of formula (ii) and e is 0, 1, 2 or 3.

13. (Previously Presented) The compound according to claim 1, wherein R³ is a group of formula (ii) and d is 0.

14. (Previously Presented) The compound according to claim 1, wherein wherein R³ is a group of formula (ii) and each R⁶ is the same or different and is independently selected from the group consisting of H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, -OR⁷, -S(O)_fR⁷, -SO₂NR⁷R⁸, -NR⁷R⁸, -N(R⁷)S(O)₂R⁸, -NO₂ and -CN.


15. (Previously Presented) The compound according to claim 1, wherein n is 0, 1 or 2.

16. (Previously Presented) The compound according to claim 1, wherein Q² is defined wherein bb is 1 and Y² is -O-, -S(O)_f-, -N(R⁷)-, -C(O)-, -OC(O)-, -CO₂-, -C(O)N(R⁷)-, -OS(O)₂-, -N(R⁷)S(O)₂-, -N(R⁷)C(O)-, -N(R⁷)CO₂- and -N(R⁷)C(O)N(R⁷)-.

17. (Previously Presented) The compound according to claim 1, wherein cc is 1.

10/522,958
PU4870USw

18. (Previously Presented) The compound according to claim 1, wherein each R^4 is the same or different and is independently selected from the group consisting of H, halo, alkyl, alkenyl, alkynyl, $-C(O)NR^7R^8$, $-OR^7$, $-S(O)_2R^7$, $-S(O)_2NR^7R^8$, $-NR^7R^8$, $-N(R^7)C(O)R^8$, $-N(R^7)S(O)_2R^8$, $-NO_2$, $-CN$, $-N_3$ and a group of formula (ii):



19. (Currently Amended) The compound according to claim 1, wherein R^5 is H, halo, alkyl or $-NR^7R^8$.

20. (Currently Amended) A compound selected from the group consisting of:
 5-(5,6-Dimethoxy-1*H*-benzimidazol-1-yl)-3-([2-(trifluoromethyl)-benzyl]oxy)thiophene-2-carboxamide;
 5-(5-(Methyloxy)-6-([2-(4-methyl-1-piperazinyl)ethyl]oxy)-1*H*-benzimidazol-1-yl)-3-([2-(trifluoromethyl)phenyl]methyl)oxy)-2-thiophenecarboxamide;
 3-[1-(2-Chlorophenyl)ethoxy]-5-(5,6-dimethoxy-1*H*-benzimidazol-1-yl)thiophene-2-carboxamide;
 5-(5,6-Dimethoxy-1*H*-benzimidazol-1-yl)-3-[1-(2-methylphenyl)ethoxy] thiophene-2-carboxamide;
 5-(5-Amino-1*H*-benzimidazol-1-yl)-3-[1-(2-chlorophenyl)ethoxy]thiophene-2-carboxamide;
 5-{6-[(4-Piperidinylmethyl)oxy]-1*H*-benzimidazol-1-yl}-3-([2-(trifluoromethyl)phenyl]methyl)oxy)-2-thiophenecarboxamide;
 5-(6-(Methyloxy)-5-([3-(2-oxo-1-pyrrolidinyl)propyl]oxy)-1*H*-benzimidazol-1-yl)-3-([2-(trifluoromethyl)phenyl]methyl)oxy)-2-thiophenecarboxamide;
 5-[6-([3-(Dimethylamino)propyl]oxy)-5-(methyloxy)-1*H*-benzimidazol-1-yl]-3-([2-(trifluoromethyl)phenyl]methyl)oxy)-2-thiophenecarboxamide;
 5-(5-(Methyloxy)-6-([2-(4-morpholinyl)ethyl]oxy)-1*H*-benzimidazol-1-yl)-3-([2-(trifluoromethyl)phenyl]methyl)oxy)-2-thiophenecarboxamide;
 5-[6-(2-Morpholin-4-ylethoxy)-1*H*-benzimidazol-1-yl]-3-([2-(trifluoromethyl)benzyl]oxy)thiophene-2-carboxamide;
 5-[6-(2-Pyrrolidin-1-ylethoxy)-1*H*-benzimidazol-1-yl]-3-([2-(trifluoromethyl)benzyl]oxy)thiophene-2-carboxamide;

10/522,958
PU4870USw

5-[5-Fluoro-6-(2-morpholin-4-ylethoxy)-1*H*-benzimidazol-1-yl]-3-[[2-(trifluoromethyl)benzyl]oxy]thiophene-2-carboxamide;
5-[6-(Methylsulfonyl)-1*H*-benzimidazol-1-yl]-3-[[2-(trifluoromethyl)benzyl]oxy]thiophene-2-carboxamide;
3-[(3-Bromopyridin-4-yl)methoxy]-5-(5,6-dimethoxy-1*H*-benzimidazol-1-yl)thiophene-2-carboxamide;
5-(5,6-Dimethoxy-1*H*-benzimidazol-1-yl)-3-[[2-(trifluoromethoxy)benzyl]oxy]thiophene-2-carboxamide;
3-[[2-(Difluoromethoxy)benzyl]oxy]-5-(5,6-dimethoxy-1*H*-benzimidazol-1-yl)thiophene-2-carboxamide;
3-[(2-Chloropyridin-3-yl)methoxy]-5-(5,6-dimethoxy-1*H*-benzimidazol-1-yl)thiophene-2-carboxamide;
5-(5,6-Dimethoxy-1*H*-benzimidazol-1-yl)-3-[(2-fluoropyridin-3-yl)methoxy]thiophene-2-carboxamide;
3-[(2-Aminopyridin-4-yl)methoxy]-5-(5,6-dimethoxy-1*H*-benzimidazol-1-yl)thiophene-2-carboxamide;
3-[(6-Chloro-1,3-benzodioxol-5-yl)methoxy]-5-(5,6-dimethoxy-1*H*-benzimidazol-1-yl)thiophene-2-carboxamide;
5-(5,6-Dimethoxy-1*H*-benzimidazol-1-yl)-3-[(2-nitrobenzyl)oxy]thiophene-2-carboxamide;
3-[(3-Aminobenzyl)oxy]-5-(5,6-dimethoxy-1*H*-benzimidazol-1-yl)thiophene-2-carboxamide;
5-(6-Bromo-1*H*-benzimidazol-1-yl)-3-[[2-(trifluoromethyl)benzyl]oxy]thiophene-2-carboxamide;
3-[(2,6-Dichlorobenzyl)oxy]-5-(5,6-dimethoxy-1*H*-benzimidazol-1-yl)thiophene-2-carboxamide;
3-[(2-Bromobenzyl)oxy]-5-(5,6-dimethoxy-1*H*-benzimidazol-1-yl)thiophene-2-carboxamide;
5-(5,6-Dimethoxy-1*H*-benzimidazol-1-yl)-3-[(2-formylbenzyl)oxy]thiophene-2-carboxamide;
5-(1*H*-Benzimidazol-1-yl)-3-[[2-(trifluoromethyl)benzyl]oxy]thiophene-2-carboxamide;
5-(1*H*-Benzimidazol-1-yl)-3-[(2-nitrobenzyl)oxy]thiophene-2-carboxamide;
5-(6-Methoxy-1*H*-benzimidazol-1-yl)-3-[[2-(trifluoromethyl)benzyl]oxy]thiophene-2-carboxamide;

10/522,958
PU4870USw

2-(Aminocarbonyl)-5-(5,6-dimethoxy-1*H*-benzimidazol-1-yl)thien-3-yl 2-methylbenzenesulfonate

and pharmaceutically acceptable salts, solvates and physiologically functional derivatives thereof.

21. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.

22. (Cancelled)

23. (Original) The pharmaceutical composition according to claim 21 further comprising a chemotherapeutic agent.

24. (Cancelled)

25. (Previously Presented) A method for treating a susceptible neoplasm in an animal, said method comprising administering to the animal a therapeutically effective amount of a compound according to claim 1.

26. (Original) The method according to claim 25, wherein said susceptible neoplasm is selected from the group consisting of breast cancer, colon cancer, lung cancer, prostate cancer, lymphoma, leukemia, endometrial cancer, melanoma, ovarian cancer, pancreatic cancer, squamous carcinoma, carcinoma of the head and neck, and esophageal carcinoma.


27. (Previously Presented) A method for treating a condition characterized by inappropriate cellular proliferation in an animal, said method comprising administering to the animal a therapeutically effective amount of a compound according to claim 1.

28. (Previously Presented) A method for inhibiting proliferation of a cell, said method comprising contacting the cell with an amount of a compound according to claim 1 sufficient to inhibit proliferation of the cell.


10/522,958
PU4870USw

29. (Previously Presented) A method for inhibiting mitosis in a cell, said method comprising administering to the cell an amount of a compound according to claim 1 sufficient to inhibit mitosis in the cell.

30. (Previously Presented) A process for preparing a compound according to claim 1, said process comprising reacting a compound of formula (III):



with a compound of formula (IV):




wherein R^{10} is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and suitable carboxylic acid protecting groups.

31-32. (Cancelled)

33-42. (Canceled).

43. (Currently Amended) A compound of formula (Ib):



wherein:

R^1 is selected from the group consisting of H, alkyl, alkenyl, alkynyl, $-C(O)R^7$, $-CO_2R^7$, $-C(O)NR^7R^8$, $-C(O)N(R^7)OR^8$, $-C(O)N(R^7)-R^2-OR^8$, $-C(O)N(R^7)-Ph$, $-C(O)N(R^7)-R^2-Ph$, $-C(O)N(R^7)C(O)R^8$, $-C(O)N(R^7)CO_2R^8$, $-C(O)N(R^7)C(O)NR^7R^8$, $-C(O)N(R^7)S(O)_2R^8$, $-R^2-OR^7$, $-R^2-O-C(O)R^7$, $-C(S)R^7$, $-C(S)NR^7R^8$, $-C(S)N(R^7)-Ph$, $-C(S)N(R^7)-R^2-Ph$, $-R^2-SR^7$, $-C(=NR^7)NR^7R^8$, $-C(=NR^7)N(R^8)-Ph$, $-C(=NR^7)N(R^8)-R^2-Ph$, $-R^2-NR^7R^8$, $-CN$, $-OR^7$, $-S(O)_2R^7$, $-S(O)_2NR^7R^8$, $-S(O)_2N(R^7)-Ph$, $-S(O)_2N(R^7)-R^2-Ph$, $-NR^7R^8$, $N(R^7)-Ph$, $-N(R^7)-R^2-Ph$,

10/522,958
PU4870USw

$-N(R^7)-SO_2R^8$ and tetrazole ~~Het~~;

Ph is phenyl optionally substituted from 1 to 3 times with a substituent selected from the group consisting of halo, alkyl, $-OH$, $-R^2-OH$, $-O-alkyl$, $-R^2-O-alkyl$, $-NH_2$, $-N(H)alkyl$, $-N(alkyl)_2$, $-CN$ and $-N_3$;

Het is a 5-7 membered heterocycle having 1, 2, 3 or 4 heteroatoms selected from N, O and S, or a 5-6 membered heteroaryl having 1, 2, 3 or 4 heteroatoms selected from N, O and S, each optionally substituted from 1 to 2 times with a substituent selected from the group consisting of halo, alkyl, oxo, $-OH$, $-R^2-OH$, $-O-alkyl$, $-R^2-O-alkyl$, $-NH_2$, $-N(H)alkyl$, $-N(alkyl)_2$, $-CN$ and $-N_3$;

n is 0, 1, 2, 3 or 4;

Q^2 is a group of formula: $-(R^2)_{aa}-(Y^2)_{bb}-(R^2)_{cc}-R^4$


~~or two adjacent Q^2 groups are selected from the group consisting of alkyl, alkenyl, OR^7 , $S(O)_2R^7$ and NR^7R^8 and together with the carbon atoms to which they are bound, they form a C_{6-8} cycloalkyl, C_{5-6} cycloalkenyl, phenyl, 5-7 membered heterocycle having 1 or 2 heteroatoms selected from N, O and S, or 5-6 membered heteroaryl having 1 or 2 heteroatoms selected from N, O and S;~~

aa, bb and cc are the same or different and are each independently 0 or 1;

each Y^2 is the same or different and is independently selected from the group consisting of $-O-$, $-S(O)_2-$, $-N(R^7)-$, $-C(O)-$, $-OC(O)-$, $-CO_2-$, $-C(O)N(R^7)-$, $-C(O)N(R^7)S(O)_2-$, $-OC(O)N(R^7)-$, $-OS(O)_2-$, $-S(O)_2N(R^7)-$, $-S(O)_2N(R^7)C(O)-$, $-N(R^7)S(O)_2-$, $-N(R^7)C(O)-$, $-N(R^7)CO_2-$ and $-N(R^7)C(O)N(R^7)-$;

each R^2 is the same or different and is independently selected from the group consisting of alkylene, alkenylene and alkynylene;

each R^4 is the same or different and is each independently selected from the group consisting of H, halo, alkyl, alkenyl, alkynyl, $-C(O)R^7$, $-C(O)NR^7R^8$, $-CO_2R^7$, $-C(S)R^7$, $-C(S)NR^7R^8$, $-C(=NR^7)R^8$, $-C(=NR^7)NR^7R^8$, $-CR^7=N-OR^7$, $-OR^7$, $-S(O)_2R^7$, $-S(O)_2NR^7R^8$, $-NR^7R^8$, $-N(R^7)C(O)R^8$, $-N(R^7)S(O)_2R^8$, $-NO_2$, $-CN$, $-N_3$ and a group of formula (ii):



ii

wherein:

Ring A is selected from the group consisting of C_{5-10} cycloalkyl,

10/522,958
PU4870USw

C₅₋₁₀cycloalkenyl, aryl, 5-10 membered heterocycle having 1, 2 or 3 heteroatoms selected from N, O and S and 5-10 membered heteroaryl having 1, 2 or 3 heteroatoms selected from N, O and S

each d is 0 or 1;

e is 0, 1, 2, 3 or 4;

each R⁶ is the same or different and is independently selected from the group consisting of H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ph, Het, -CH(OH)-R²-OH, -C(O)R⁷, -CO₂R⁷, -CO₂-R²-Ph, -CO₂-R²-Het, -C(O)NR⁷R⁸, -C(O)N(R⁷)C(O)R⁷, -C(O)N(R⁷)CO₂R⁷, -C(O)N(R⁷)C(O)NR⁷R⁸, -C(O)N(R⁷)S(O)₂R⁷, -C(S)R⁷, -C(S)NR⁷R⁸, -C(=NR⁷)R⁸, -C(=NR⁷)NR⁷R⁸, -CR⁷=N-OR⁸, =O, -OR⁷, -OC(O)R⁷, -OC(O)Ph, -OC(O)Het, -OC(O)NR⁷R⁸, -O-R²-S(O)₂R⁷, -S(O)₂R⁷, -S(O)₂NR⁷R⁸, -S(O)₂Ph, -S(O)₂Het, -NR⁷R⁸, -N(R⁷)C(O)R⁸, -N(R⁷)CO₂R⁸, -N(R⁷)-R²-CO₂R⁸, -N(R⁷)C(O)NR⁷R⁸, -N(R⁷)-R²-C(O)NR⁷R⁸, -N(R⁷)C(O)Ph, -N(R⁷)C(O)Het, -N(R⁷)Ph, -N(R⁷)Het, -N(R⁷)C(O)NR⁷-R²-NR⁷R⁸, -N(R⁷)C(O)N(R⁷)Ph, -N(R⁷)C(O)N(R⁷)Het, -N(R⁷)C(O)N(R⁷)-R²-Het, -N(R⁷)S(O)₂R⁸, -N(R⁷)-R²-S(O)₂R⁸, -NO₂, -CN and -N₃;

wherein when Q² is defined where bb is 1 and cc is 0, R⁴ is not halo, -C(O)R⁷, -C(O)NR⁷R⁸, -CO₂R⁷, -C(S)R⁷, -C(S)NR⁷R⁸, -C(=NR⁷)R⁸, -C(=NR⁷)NR⁷R⁸, -CR⁷=N-OR⁷, -OR⁷, -S(O)₂R⁷, -S(O)₂NR⁷R⁸, -NR⁷R⁸, -N(R⁷)C(O)R⁸, -N(R⁷)S(O)₂R⁸, -NO₂, -CN or -N₃;

R⁵ is selected from the group consisting of H, halo, alkyl, cycloalkyl, OR⁷, -S(O)₂R⁷, -NR⁷R⁸, -NHC(O)R⁷, -NHC(O)NR⁷R⁸ and -NHS(O)₂R⁷;

f is 0, 1 or 2; and

each R⁷ and each R⁸ are the same or different and are each independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl; and

each R⁹ is the same or different and is selected from H, halo and alkyl;


or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.

44. (Previously Presented) An R-isomer of a compound according to claim 43.

10/522,958
PU4870USw

45. (Canceled)

46. (Previously Presented) A compound of formula (Ib):



wherein:

R^1 is $-C(O)NH_2$;

each R^9 is the same or different and is selected from H, halo and alkyl;

Ring A is phenyl;

d is 0;

e is 1;

R^8 is trifluoromethyl;

n is 1 and Q^2 is at C-6;

R^5 is H;

f is 0, 1 or 2; and

each R^7 and each R^8 are the same or different and are each independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl; and


Q^2 is a group of formula: $-(R^2)_{aa}-(Y^2)_{bb}-(R^2)_{cc}-R^4$, wherein:

aa is 0;

bb is 0;

cc is 1 and $(R^2)_{cc}$ is C_{1-3} alkylene; and

R^4 is a group of formula (ii):



wherein:

Ring A is selected from the group consisting of morpholine, piperidine, piperazine, phenyl, pyrrolidinone, imidazolidinone and pyrrolidine

d is 0;

e is 1; and

10/522,958
PU4870USw

R^6 is selected from the group consisting of H, halo, alkyl, =O, -OR⁷,
-S(O)_nR⁷, -S(O)₂NR⁷R⁸ and -NR⁷R⁸;
or a pharmaceutically acceptable salt thereof.